Navigation Links
Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
Date:8/14/2014

ROCKVILLE, Md., Aug. 14, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three and six months ended June 30, 2014, and provided an operational progress update.

Jeffrey Riley, CEO of Synthetic Biologics, stated, "We have accomplished key goals in all of our pipeline programs, further built infrastructure, including GMP manufacturing resources to support these activities, and filed new patent applications covering our C-IBS and Pertussis programs, as well as in the Trimesta program for multiple sclerosis (MS).

"Of particular note, I am pleased to report that significant progress has been made in further analysis of the clinical outcomes in the Phase II MS study of Trimesta since topline results were presented in April 2014. It is important to emphasize that patients treated with Trimesta benefited from the dual mode of action of the drug, including the anti-inflammatory effects that improve relapse rate, as well as the potential neuroprotective effects that improve disability and cognition measures. Additional MRI analyses are ongoing to evaluate changes in the brain that correlate with the improvements seen in clinical outcome. The expanded data from the trial continues to build our confidence in the high value of this program for patients with MS.

"In addition, we have completed plans to file INDs and initiate clinical trials this year for our C. difficile and C-IBS programs, both of which are expected to report topline Phase II data in mid-2015. We also have plans to file an IND and start Phase I testing during the first half of next year of our novel monoclonal antibody cocktail as a first-in-class candidate for the prevention and treatment of Pertussis (whooping cough)."

Mr. Riley added
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
2. Synthetic Biologics to Report Second Quarter 2014 Financial Results
3. Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
4. Global Synthetic Biology Market 2014-2018
5. Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference
6. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
7. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
8. Synthetic Biologics Announces Proposed Public Offering of Common Stock
9. Global Geosynthetics Market 2012-2016
10. Process holds promise for production of synthetic gasoline
11. Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  A group of biotechnology executives ... Coma Research Institute, a non-profit organization dedicated to providing ... suffering from disorders of consciousness.  ...   ... in which no voluntary actions can be initiated by ...
(Date:5/5/2015)... May 5, 2015 CytomX, a biotechnology company ... announced that Sean McCarthy , D. Phil., chief ... Day in New York at ... will present an overview of CytomX,s Probody pipeline, including ... programs. About CytomX Therapeutics CytomX Therapeutics ...
(Date:5/5/2015)...  Indianapolis-based medical device manufacturer NICO Corporation is ... products including the BrainPath® and Myriad™ technologies offering ... abnormalities and then removing affected tissue. More than ... 50 institutions throughout the United States ... in 12 abstracts, three peer-reviewed publications, and seven ...
(Date:5/4/2015)... /PRNewswire/ - JSS Medical Research Inc., a Montreal ... the acquisition of Max Neeman International (MNI), with head office in ... located in Ahmedabad, Bangalore , Chennai ... subsidiary, a regional office is located North Carolina, USA ... the recent equity investment transaction into JSS with Capital Croissance PME ...
Breaking Biology Technology:Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4
... about these days stirs as much feedback as my columns ... tools, search, social networks, and syndication technologies. , ,Over the ... social networks to a cautious blogger, and now an enthusiastic ... force that is fundamentally changing communications on every facet. , ...
... than ever before, experts at AD:TECH Chicago agreed, ... quickly sink a product or company's reputation. The result? More ... for companies to watch their brandsand their backs. , ,Several ... companies need to focus more on maintaining their online presence ...
... a rainbow arches from its HQ all the way to prison. ... sheds its old image of ENWRONG to PRISMA. After paying $665 ... identity of PRISMA while some of its executives walk to prison. ... a staff of 5000 in 25 different business units, a big ...
Cached Biology Technology:Changing perspectives on social networks 2Changing perspectives on social networks 3AD:TECH: Advertisers face harsh lessons at the hands of powerful consumers 2AD:TECH: Advertisers face harsh lessons at the hands of powerful consumers 3AD:TECH: Advertisers face harsh lessons at the hands of powerful consumers 4Why is Enron now called Prisma? 2Why is Enron now called Prisma? 3
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... shows that anti-microbial medications are a common cause of ... (ALF), with women and minorities disproportionately affected. While ALF ... is unlikely; however liver transplantation offers an excellent survival ... published in the December issue of Hepatology , ...
... SANTA CRUZ, CA--The Genome 10K Community of Scientists and BGI ... a plan to sequence the genomes of 101 vertebrate species ... 10,000 species to be sequenced by the Genome 10K Project. ... effort to gather specimens of thousands of animals from zoos, ...
... On Nov. 16, 2010, at the annual AHA meeting in ... Arnold M. Katz Basic Science Research Prize for Young Investigators. ... and molecular physiology, and a member of the McAllister Heart ... N. and Arnold M. Katz Prize is one of the ...
Cached Biology News:Study finds anti-microbials a common cause of drug-induced liver injury and failure 2Genome 10K Project announces first 101 species for genome sequencing 2Genome 10K Project announces first 101 species for genome sequencing 3
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
GBL Antibody...
Biology Products: